BankUnited reported Q2 2026 earnings per share of $0.97 and revenues of $284.57 million, both below analyst expectations. Despite the earnings miss, the bank achieved record growth in non-interest-bearing demand deposits, which reached 34.4% of total deposits, providing a low-cost funding source. Jefferies maintained a "Buy" rating but lowered the price target from $60 to $55, reflecting cautious optimism amid mixed results. The stock fell 5.63% following the earnings announcement, but the strong deposit base signals potential for future stability and growth.
Arrowhead Pharmaceuticals saw its stock rise over 21% after positive late-stage trial results for its drug plozasiran, which significantly lowered triglyceride levels in patients with severe hypertriglyceridemia. Chardan Capital raised the price targ...
UBS has maintained a Market Perform rating on Comcast stock ahead of its Q2 earnings report, reflecting caution due to expected declines. Comcast is projected to report a 22.4% drop in earnings per share to $0.97 and a 3.75% revenue decrease to about...
City Holding Company reported strong Q2 2026 results with earnings per share (EPS) of $2.35, beating analyst estimates by nearly 6%. Quarterly revenue reached $81.52 million, up 4.3% year-over-year and slightly above expectations. This marks continue...
Rogers Communication reported better-than-expected Q2 2026 results, with earnings per share of $0.83 beating estimates of $0.80 and revenue reaching $3.96 billion, surpassing forecasts. The company showed improved financial discipline by increasing f...
The global Botulinum Toxin in Urology Market is projected to grow from approximately USD 1.16 billion in 2026 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is fueled by increasing prevalence of urological disorders like overactive bladder, ...
